• 1
    NIH Consens State Sci Statements. 2002 Jun 10–12;19(3): 146.
  • 2
    Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 1998; 143: 24932503.
  • 3
    Hnatyszyn HJ. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antiviral Ther 2005; 10: 111.
  • 4
    World Health Organization. Hepatitis C. WHO fact sheet 164. Available at: Accessed May 21, 2007.
  • 5
    Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005; 3(Suppl 2): S97S101.
  • 6
    Egyptian Ministry of Health. Egyptian Ministry of Health Annual Report: 2007. Available at Accessed 10 August 2007.
  • 7
    Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. HEPATOLOGY 2000; 32: 111115.
  • 8
    Rapicetta M, Argentini C, Dettori S, Spada E, Pellizzer G, Gandin C. Molecular heterogeneity and new subtypes of HCV genotype 4. Res Virol 1998; 149: 293297.
  • 9
    Simmonds P, McOmish F, Yap PL, Chan S-W, Lin CK, Dusheiko G, et al. Sequence variability in the 5' non-coding region of hepatitis C virus : identification of a new virus type and restrictions on the sequence diversity. J Gen Virol 1993; 74: 661668.
  • 10
    Simmonds P, Holmes EC, Cha T-A, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74: 23912399.
  • 11
    Bhattacherjee V, Prescott LE, Pike I, Rodgers B, Bell H, El-Zayadi AR, et al. Use of NS-4 peptides to identify type specific antibody to hepatitis C virus genotypes 1, 2, 3, 4, 5 and 6. J Gen Virol 1995; 76: 17371748.
  • 12
    Chamberlain R, Adams N, Saeed AA, Simmonds P, Elliott RM. Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. J Gen Virol 1997; 78: 13411347.
  • 13
    Los Alamos National Laboratory. Los Alamos HCV Database. Available at: Accessed 9 August 2007.
  • 14
    Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. HEPATOLOGY 2005; 42: 962973.
  • 15
    Timm J, Neukamm M, Kuntzen T, Kim A, Chung R. T, Brander C, et al. Characterization of full-length hepatitis C virus genotype 4 sequences J Viral Hepat 2007; 14: 330337.
  • 16
    Simmonds P. Genetic diversity and evolution of hepatitis C virus—15 years on. J Gen Virol 2004; 85: 31733188.
  • 17
    Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, Yap PL, et al. The origin of hepatitis C virus genotypes. J Gen Virol 1997; 78: 321328.
  • 18
    Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, et al.; Observational VHC4 Study Group. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14: 460467.
  • 19
    Abdel Hamid M, El Daly M, Molnegren V, El-Kafrawy S, Abdel-Latif S, Esmat G, et al. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol 2007; 88: 15261531.
  • 20
    Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197: 16451655.
  • 21
    Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 14991512.
  • 22
    Genovese D, Dettori S, Argentini C, Villano U, Chionne P, Angelico M, et al. Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis. J Clin Microbiol 2005; 43: 19021909.
  • 23
    Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000; 182: 698707.
  • 24
    Xu L-Z, Larzul D, Delaporte E, Bréchot C, Kremsdorf D. Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). J Gen Virol 1994; 75: 23932398.
  • 25
    Ndjomou J, Pybus OG, Matz B. Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon. J Gen Virol 2003; 84: 23332341.
  • 26
    Njouom R, Nerrienet E, Dubois M, Lachenal G, Rousset D, Vessière A, et al. The hepatitis C virus epidemic in Cameroon: genetic evidence for rapid transmission between 1920 and 1960. Infect Genet Evol 2007; 7: 361367.
  • 27
    Pybus O, Drummond A, Nakano T, Robertson BH, Rambaut A. The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. Mol Biol Evol 2003; 20: 381387.
  • 28
    Tanaka Y, Agha S, Saudy N, Kurbanov F, Orito E, Kato T, et al. Exponential spread of hepatitis C virus genotype 4a in Egypt. J Mol Evol 2004; 58: 191195.
  • 29
    Angelico M, Renganathan E, Gandin C, Fathy M, Profili MC, Refai W, et al. Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections. J Hepatol 1997; 26: 236243.
  • 30
    Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C in Egypt. Lancet 2000; 355: 887891.
  • 31
    Kamal S, Madwar M, Bianchi L, Tawil AE, Fawzy R, Peters T, et al. Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni. Liver 2000; 20: 281289.
  • 32
    Habib M, Mohamed MK, Abdel-Aziz F, Magder LS, Abdel-Hamid M, Gamil F, et al. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. HEPATOLOGY 2001; 33: 248253.
  • 33
    Zakaria S, Fouad R, Shaker O, Zaki S, Hashem A, El-Kamary SS, et al. Changing patterns of acute viral hepatitis at a major urban referral center in Egypt. Clin Infect Dis 2007; 44: e30e36.
  • 35
    Stoszek SK, Abdel-Hamid M, Narooz S, El Daly M, Saleh DA, Mikhail N, et al. Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women. Trans R Soc Trop Med Hyg 2006; 100: 102107.
  • 36
    El Katsha S, Labeeb S, Watts S, Younis A. Informal health providers and the transmission of hepatitis C virus: pilot study in two Egyptian villages. East Mediterr Health J 2006; 12: 758767.
  • 37
    Talaat M, Kandeel A, El-Shoubary W, Bodenschatz C, Khairy I, Oun S, et al. Occupational exposure to needlestick injuries and hepatitis B vaccination coverage among health care workers in Egypt. Am J Infect Control 2003; 31: 469474.
  • 38
    Kamal SM, Amin A, Madwar M, Graham CS, He Q, Al Tawil A, et al. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol 2004; 78: 1225212258.
  • 39
    Magder LS, Fix AD, Mikhail NN, Mohamed MK, Abdel-Hamid M, Abdel-Aziz F, et al. Estimation of the risk of transmission of hepatitis C between spouses in Egypt based on seroprevalence data. Int J Epidemiol 2005; 34: 160165.
  • 40
    Mohamed MK, Abdel-Hamid M, Mikhail NN, Abdel-Aziz F, Medhat A, Magder LS, et al. Intrafamilial transmission of hepatitis C in Egypt. HEPATOLOGY 2005; 42: 683687.
  • 41
    Shobokshi OA, Serebour FE, Skakni L, Al-Saffy YH, Ahdal MN. Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 1999; 58: 4448.
  • 42
    Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millennium: the GEMHEP GenoCII Study. J Viral Hepat 2005; 12: 405413.
  • 43
    Nicot F, Legrand-Abravanel F, Sandres-Saune K, Boulestin A, Dubois M, Alric L, et al. Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France. J Gen Virol 2005; 86: 107114.
  • 44
    Ansaldi F, Bruzzone B, Salamaso S, Rota MC, Durando P, Gasparini R, et al. Different seroprelavence and molecular epidemiology pattern of hepatitis C virus infection in Italy. J Med Virol 2005; 76: 327332.
  • 45
    Katsoulidou A, Sypsa V, Tassopoulos NC, Boletis J, Karafoulidou A, Ketikoglou I, et al. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat 2006; 13: 1927.
  • 46
    Fernandez-Arcas N, Lopez-Siles J, Trapero S, Ferraro A, Ibanez A, Orihuela F, et al. High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): phylogenetic and epidemiological analyses. J Med Virol 2006; 78: 14291435.
  • 47
    Franco S, Tural C, Clotet B, Martínez MA. Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1. Virus Res 2007; 123: 161169.
  • 48
    Lyra AC, Ramrakhiani S, Bacon BR, Di Bisceglie AM. Infection with hepatitis C virus genotype 4 in the United States. J Clin Gastroenterol 2004; 38: 6871.
  • 49
    Zein N, Rakela J, Krawitt E, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Int Med 1996; 125: 634639.
  • 50
    Seeff L. Natural history of chronic hepatitis C. HEPATOLOGY 2002; 36(Suppl 1): S35S46.
  • 51
    Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 764767.
  • 52
    De Moliner L, Pontisso P, De Salvo GL, Cavalletto L, Chemello L, Alberti A. Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut 1998; 42: 856860.
  • 53
    Roffi L, Ricci A, Ogliari C, Scalori A, Minola E, Colloredo G, et al. HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol 1998; 29: 701706.
  • 54
    Harris HE, Eldridge KP, Harbour S, Alexander G, Teo CG, Ramsay ME. The HCV National Register Steering Group*. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? J Viral Hepat 2007; 14: 213220.
  • 55
    Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. HEPATOLOGY 2006; 43: 923931.
  • 56
    Santantonio T, Medda E, Ferrari C, Fabris P, Cariti G, Massari M, et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis 2006; 43: 11541159.
  • 57
    Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13: 3441.
  • 58
    Kamal SM, Rasenack JW, Bianchi L, Al Tawil A, El Sayed Khalifa K, Peter T, et al. Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response. Gastroenterology 2001; 121: 646656.
  • 59
    Gambotti L, Batisse D, Colin-de-Verdiere N, Delaroque-Astagneau E, Desenclos JC, Dominguez S, et al.; Acute Hepatitis C Collaborating Group. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001–2004. Euro Surveill 2005; 10: 115117.
  • 60
    Kamal SM, Graham CS, He Q, Bianchi L, Tawil AA, Rasenack JW, et al. Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis. J Infect Dis 2004; 189: 11401150.
  • 61
    Kamal SM, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. HEPATOLOGY 2006; 43: 771779.
  • 62
    Esmat G, Metwally M, Zalata KR, Gadalla S, Abdel-Hamid M, Abouzied A, et al. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol 2007; 46: 620627.
  • 63
    Maida I, Soriano V, Barreiro P, Rivas P, Labarga P, Núñez M. Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases. AIDS Res Hum Retroviruses 2007; 23: 801804.
  • 64
    Tsochatzis E, Papatheodoridis GV, Manesis EK, Chrysanthos N, Kafiri G, Petraki K, et al. Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. Am J Gastroenterol 2007; 102: 634641.
    Direct Link:
  • 65
    Zayadi A, Attia M, Barakat EM, Zalata K, Saeid A, Hamdy H, et al. Non-alcoholic fatty liver disease in patients with HCV genotype 4. Gut 2007; 56: 11701171.
  • 66
    Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. HEPATOLOGY 2007; 46: 17321740.
  • 67
    Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G, et al. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006; 13: 7380.
  • 68
    Patel K, Zekry A, McHutchison JG. Steatosis and chronic hepatitis C virus infection: mechanisms and significance. Clin Liv Dis 2005; 9: 399410.
  • 69
    Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al.; HCV Meta-Analysis (on) Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 16361642.
  • 70
    Zein NN, Poterucha JJ, Gross JB Jr, Wiesner RH, Therneau TM, Gossard AA, et al. Increased risk of hepatocellular carcinoma in patients infected with hepatitis C genotype 1b. Am J Gastroenterol 1996; 91: 25602562.
  • 71
    Tanaka K, Ikematsu H, Hirohata T, Kashiwagi S. Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: possible role of type 1b (II) infection. J Natl Cancer Inst 1996; 88: 742746.
  • 72
    Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli M. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. HEPATOLOGY 2007; 46: 13501356.
  • 73
    National Cancer Registry of Egypt. Magnitude of hepatocellular carcinoma in Egypt. Available at: Accessed 3 August 2007.
  • 74
    FreedmanLS, EdwardsBK, RiesLAG, YoungJL, eds. Cancer Incidence in Four Member Countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER. NIH Pub. No. 06-5873. Bethesda, MD: National Cancer Institute; 2006.
  • 75
    Ezzat S, Abdel-Hamid M, Eissa SA, Mokhtar N, Labib NA, El-Ghorory L, et al. Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. Int J Hyg Environ Health 2005; 208: 329339.
  • 76
    Sugo H, Balderson GA, Crawford DH, Fawcett J, Lynch SV, Strong RW, et al. The influence of viral genotypes and rejection episodes on the recurrence of hepatitis C after liver transplantation. Surg Today 2003; 33: 421425.
  • 77
    Gordon FD, Poterucha JJ, Germer J, Zein NN, Batts KP, Gross JB Jr, et al. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation. Transplantation 1997; 63: 14191423.
  • 78
    Zekry A, Whiting P, Crawford DH, Angus PW, Jeffrey GP, Padbury RT, et al. Liver transplantation forHCV associated liver cirrhosis: Predictors of outcomes in a population with significant genotype 3 and 4 distribution. Liver Transpl 2003; 9: 339347.
  • 79
    Wali MH, Heydtmann M, Harrison RF, Gunson BK, Mutimer DJ. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transplantation 2003; 9: 796804.
  • 80
    Zylberberg H, Chaix ML, Brechot C. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Ann Intern Med 2000; 132: 845846.
  • 81
    Kamal SM, Madwar MA, Peters T, Fawzy R, Rasenack J. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol 2000; 32: 172174.
  • 82
    Koshy A, Marcellin P, Martinot M, Madda JP. Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. Liver 2000; 20: 335339.
  • 83
    Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, Alashgar H, et al. Peginterferon a-2b plus ribavirin compared with interferon a-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004; 24: 568574.
  • 84
    Esmat G, Abouzied AM, Abdel-Aziz F, Strickland T. Subjects with chronic hepatitis C and genotype 4 have a similarly effective response to standard or pegylated interferon in combination with ribavirin [Abstract]. HEPATOLOGY 2003; 38(Suppl): 324A.
  • 85
    Shobokshi OA, Serebour FE, Skakni L, Al Khalifa M. Combination therapy of peginterferon alfa-2a and ribavirin significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia [Abstract]. HEPATOLOGY 2003; 38(Suppl): 996A.
  • 86
    Thakeb FAI, Omar MM, El Awadi MM, Isshak SY. Randomized controlled trial of peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus genotype 4 among Egyptian patients [Abstract]. HEPATOLOGY 2003; 38: 252A.
  • 87
    Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004; 99: 17331737.
    Direct Link:
  • 88
    Diago M, Hassanein T, Rodes J, Ackrill AM, Sedarati F. Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. Ann Intern Med 2004; 140: 7273.
  • 89
    Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2004; 20: 931938.
  • 90
    Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SK, et al. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 858866.
  • 91
    El Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of peg-interferon-a2b/ribavirin or induction-dose interferon a2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol 2005; 100: 24472452.
    Direct Link:
  • 92
    Derbala MF, Al Kaabi SR, El Dweik NZ, Pasic F, Butt MT, Yakoob R, et al. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006; 12: 56925698.
  • 93
    Trapero-Marugan M, Moreno-Monteagudo JA, Garcia-Buey L, Borque MJ, Medina J, Garcia-Sanchez A, et al. Clinical and pathological characteristics and response to combination therapy of genotype 4 chronic hepatitis C patients: experience from a spanish center. J Chemother 2007; 19: 423427.
  • 94
    Legrand-Abravanel F, Nicot F, Boulestin A, Sandres-Saune K, Vinel JP, Alric L, et al. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 2005; 77: 6669.
  • 95
    Soriano V, Nunez M, Sanchez-Conde M, Barreiro P, Garcia-Samaniego A, Martin-Carbonero L, et al. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4. Antiviral Ther 2005; 10: 167170.
  • 96
    Fontana RJ, Everson GT, Tuteja S, Vargas HE, Shiffman ML. Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clin Gastroenterol Hepatol 2004; 2: 183197.
  • 97
    Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17: 687694.
  • 98
    Wong JB, Nevens F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterol Belg 2002; 65: 110111.
  • 99
    Buti M, Casado MA, Fosbrook L, Esteban R. Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1. Pharmacoeconomics 2005; 23: 10431055.
  • 100
    Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97103.